Long-Term Effectiveness of Evolocumab in Reducing the Risk for Major Adverse Cardiovascular Events: Comparing FOURIER OLE Data to External Control Using a Principled Approach (AHA 2026) - Sep 5, 2026 - Abstract #6839; Pres time: Nov 8, 2026; 04:15 PM - 04:25 PM; Location: N231; "Abstract is embargoed at this time."
Adverse events • Cardiovascular
|
|
Swati Sakhuja, Emileigh Walsh, Amgen Inc., Thousand Oaks, CA; M. Brookhart, Duke Univ, Durham, NC; Timothy Lash, Emory Univ, Atlanta, GA; Robert Giugliano, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hosp and Harvard Medical Sch, Boston, MA; David Neasham, Amgen Ltd, Uxbridge, London, United Kingdom; Hengyi Ke, Amgen Inc., Thousand Oaks, CA; KyungAh Im, Michelle L O'Donoghue, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women’s Hosp and Harvard Medical Sch, Boston, MA; Francesco Giorgianni, Amgen Ltd, Uxbridge, London, United Kingdom; Gabriel Paiva da Silva Lima, Lyrica Liu, Shia Kent, Amgen Inc., Thousand Oaks, CA; Marc S Sabatine, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women’s Hosp and Harvard Medical Sch, Boston, MA; Nafeesa Dhalwani, Amgen Inc., Thousand Oaks, CA
|